ALX Oncology (ALXO) Competitors $1.14 -0.06 (-5.00%) Closing price 04:00 PM EasternExtended Trading$1.14 0.00 (0.00%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. IMRX, GNLX, HURA, CTOR, CLYM, ALTS, ACOG, IKT, CGEN, and SCLXShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Immuneering (IMRX), Genelux (GNLX), TuHURA Biosciences (HURA), Citius Oncology (CTOR), Climb Bio (CLYM), ALT5 Sigma (ALTS), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), Compugen (CGEN), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Its Competitors Immuneering Genelux TuHURA Biosciences Citius Oncology Climb Bio ALT5 Sigma Alpha Cognition Inhibikase Therapeutics Compugen Scilex ALX Oncology (NASDAQ:ALXO) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation. Which has stronger valuation & earnings, ALXO or IMRX? Immuneering has higher revenue and earnings than ALX Oncology. Immuneering is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.20-0.52Immuneering$320K636.74-$61.04M-$1.89-2.97 Which has more volatility and risk, ALXO or IMRX? ALX Oncology has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Do analysts rate ALXO or IMRX? ALX Oncology presently has a consensus target price of $3.30, suggesting a potential upside of 189.47%. Immuneering has a consensus target price of $13.00, suggesting a potential upside of 131.73%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe ALX Oncology is more favorable than Immuneering.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is ALXO or IMRX more profitable? ALX Oncology's return on equity of -115.67% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -115.67% -84.82% Immuneering N/A -146.28%-117.22% Do insiders and institutionals hold more shares of ALXO or IMRX? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer ALXO or IMRX? In the previous week, Immuneering had 9 more articles in the media than ALX Oncology. MarketBeat recorded 13 mentions for Immuneering and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.97 beat Immuneering's score of 0.39 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryALX Oncology beats Immuneering on 9 of the 14 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.05M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.5221.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book0.958.0710.026.67Net Income-$134.85M-$54.08M$3.27B$265.59M7 Day Performance10.68%2.26%3.17%3.42%1 Month Performance82.11%3.42%4.34%1.09%1 Year Performance-51.28%18.61%44.11%23.85% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.2051 of 5 stars$1.14-5.0%$3.30+189.5%-51.8%$61.05MN/A-0.5240Gap UpIMRXImmuneering3.5359 of 5 stars$3.50-6.9%$13.25+278.6%+359.3%$136.56M$320K-1.8560Analyst ForecastGNLXGenelux1.8363 of 5 stars$3.54-0.6%$17.75+401.4%+74.2%$134.47M$10K0.0010News CoveragePositive NewsHURATuHURA Biosciences1.5237 of 5 stars$3.09+1.0%$12.67+309.9%N/A$133.66MN/A0.00N/ACTORCitius Oncology1.3993 of 5 stars$1.75+3.6%$3.00+71.4%+14.2%$132.45MN/A0.00N/APositive NewsCLYMClimb Bio3.4023 of 5 stars$2.11+11.1%$9.00+326.5%N/A$128.75MN/A-3.019Gap UpHigh Trading VolumeALTSALT5 Sigma0.3556 of 5 stars$6.12+3.0%N/A+178.5%$128.36M$12.53M0.00170Gap UpACOGAlpha Cognition2.3425 of 5 stars$8.44+5.5%$20.00+137.0%N/A$128.16MN/A0.00N/APositive NewsIKTInhibikase Therapeutics1.7582 of 5 stars$1.72-1.7%$6.50+277.9%+27.9%$127.87MN/A-0.646CGENCompugen2.2442 of 5 stars$1.55+8.4%$4.00+158.1%-26.9%$127.61M$27.86M-7.0570News CoveragePositive NewsHigh Trading VolumeSCLXScilex2.239 of 5 stars$19.38+7.2%$455.00+2,247.8%-54.0%$125.76M$56.59M-0.6780Gap Up Related Companies and Tools Related Companies Immuneering Competitors Genelux Competitors TuHURA Biosciences Competitors Citius Oncology Competitors Climb Bio Competitors ALT5 Sigma Competitors Alpha Cognition Competitors Inhibikase Therapeutics Competitors Compugen Competitors Scilex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access